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Nucleotide sequence variation in the noncoding region of the genome of human papillomavirus type 16
(HPV16) was determined by direct sequencing and single-strand conformation polymorphism analysis of DNA
fragments amplified by PCR. Individuals of diverse sexual promiscuity and/or cervicopathology were studied.
In a group of 14 healthy, monogamous HPV16-positive females, only two HPV16 sequence variants could be
documented. Among 17 females and 3 males with multiple sex partners and living in the same geographical
region, nine sequence variants were found, whereas among 7 patients with cervical neoplasia from another
region, five variants were detected. Although numbers are limited, in the group of individuals at high risk of
acquiring a sexually transmitted disease or with cervical neoplasia, a larger number of HPV16 sequence
variants was encountered (two types among 14 individuals versus nine types among 20; Fisher’s exact test,
P 5 0.07). Seven of the individuals were sampled repeatedly over time. For these persistently infected women,
no differences in HPV16 sequences were detected, irrespective of promiscuity, and persistence of a single viral
variant, spread over multiple anatomic sites, for more than 2 years could be demonstrated. This indicates that
viral persistence may be a common feature and that successful superinfection with a new variant may be rare,
despite a potentially high frequency of viral reinoculation.
Human papillomavirus type 16 (HPV16) is implicated as a
causal agent in the development of cervical and penile carci-
noma. This implication is based on the results of large epide-
miological studies (16, 18, 21), and numerous studies analyz-
ing the mechanism of sexual transmission of HPV16 have
been initiated (1, 2, 4, 8, 9, 13). To date, however, the precise
HPV16-induced mechanisms underlying viral persistence
within an individual patient and viral spread among individuals
are still largely unknown. Basic to understanding viral pathol-
ogy are the molecular features of viral infection and persis-
tence. A prerequisite for characterization of viral behavior is
determination of genetic variation in the genome (7, 11, 12, 14,
26–28). Genetic variants of HPV can be characterized by phys-
ical analysis of genomic regions which have been amplified by
PCR. Electrophoretic typing of mutants can be performed by
single-strand conformation polymorphism (SSCP) analysis (19,
23), whereas the most-detailed identification can be attained
by sequence analysis (5). In this paper, we describe the appli-
cation of SSCP and direct sequence analysis for investigation
of PCR-amplified HPV16 DNA obtained either incidentally or
longitudinally from individual patients of diverse promiscuity
and cervicopathology.
The main goal of the present study was to assess whether
females persistently testing positive for HPV16 were infected
by the same variant for the entire screening period. Simulta-
neously, by comparing results for individuals of diverse sexual
promiscuity, the effect of frequent superinfection could be
estimated. All females positive for HPV16 were enrolled in a
long-term surveillance program, irrespective of their geograph-
ical origin. Individuals were included in the present study when
multiple clinical samples were still available. In addition, sev-
eral single samples were used to determine the basic level of
genetic variation among Dutch HPV16 strains as found in
either healthy individuals or patients with cervical neoplasia.
MATERIALS AND METHODS
Clinical samples. Clinical material was derived from individuals from Amster-
dam, Delft, Nijmegen, and Groningen, The Netherlands. For female patients,
scrapes from different body sites were obtained. In all cases, cervical smears were
obtained from the transformation zone by using Ayre spatulas which were im-
mersed in phosphate-buffered saline, pH 7 (PBS). Sampling of the anus, rectum,
or labia minora was done with wooden spatulas or cotton-tipped applicators.
Samples were transported to the laboratory in PBS and stored at 2208C. An
HPV16 strain from Nijmegen was detected in an anorectal biopsy specimen
obtained from a condylomatous wart from a female patient. The clinical origins
of all samples are described in Table 1.
Patients. HPV16-positive individuals can be grouped according to sexual pro-
miscuity or the presence of cervical neoplasia. Moreover, samples from these
patients can be characterized as incidental or as one of a longitudinally isolated
series of specimens.
The group of people with multiple heterosexual partners, of which 70% were
engaged in commercial sexual contacts, consisted of 3 men and 17 women
selected from participants in a prospective study of HPV infection carried out at
the Clinic for Sexually Transmitted Diseases of the Amsterdam Municipal
Health Service (24). Demographic characteristics and medical history, including
sexually transmitted diseases (STDs), were recorded. An additional question-
naire was used to assess the possibility of HPV-associated risk factors and sexual
practices (Table 2). For 4 of these 20 individuals (prostitutes 35 through 38;
Table 1), multiple samples, gathered over time, were available. For the other 16
individuals, incidental samples were obtained. These samples served as a refer-
ence panel for establishing the nature of the variants encountered in Amsterdam.
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For three patients, specimens collected from different anatomic sites during the
same visit were positive for HPV16.
A group of monogamous, healthy women was recruited from in and around
Delft. Fourteen females involved in a routine screening for cervical carcinoma
were included. Again, an inventory of potential HPV risk factors and sexual
practices was made. For this group, 11 incidental isolates were included. From
two females (numbers 41 and 42; Table 1), HPV16-positive samples were ob-
tained on two separate occasions, whereas from one patient (number 40), seven
consecutive HPV16-positive cervical scrapes were collected over the years.
For the third group, material from seven females from Groningen was col-
lected. This group of patients was known for having cervicopathological aberra-
tions.
Finally, a single HPV16 strain from a patient in Nijmegen was included.
DNA isolation and amplification. The scrapings were kept frozen at 2208C
until use. After thawing of the samples, tubes were vortexed rigorously for 30 s
to release cells from applicators or spatulas. After removal of the spatulas and
applicators, the tubes were centrifuged for 10 min at 3,000 rpm (Heddich Ro-
damda/AP centrifuge) and the cell pellet was resuspended in 0.5 ml of PBS. Of
this fraction, a small portion (100 ml) was treated with pronase and DNA was
isolated by phenol-chloroform-isoamyl alcohol extraction (17). The PCR assay
for diagnosis of HPV16 infection was as described before (6). Amplified DNA
was characterized by Southern blotting of analytical agarose gels and hybridiza-
tion to an HPV16-specific DNA oligonucleotide probe which was previously
labeled with [a-32P]ATP (3,000 Ci/mmol; Amersham, Buckinghamshire, United
Kingdom) and polynucleotide kinase (Promega, Leiden, The Netherlands). Hy-
bridization was under high-stringency conditions, and during amplification pos-
itive and negative control samples were included. Efficiency of the PCR was
determined by amplification of a part of the b-globin gene (20). All specimens
were positive for both HPV16 DNA and b-globin DNA. For genotyping assays,
the HPV16-positive samples were subjected to a second round of PCR. The
entire noncoding region of HPV16 was amplified in two fragments by using two
distinct primer sets (27). The region between nucleotides 7109 and 7527 (10, 22)
was amplified with primer A (CCTCATCTACCTCTACAACTGCTAAACGG)
and primer B (GTTTAAACCATAGTTGCTGACATAGAAC). An overlapping
682-nucleotide fragment (the region between nucleotides 7445 and 222 [see
references 10 and 22]) was amplified with primer C (GCTTCAACCGAATTCG
GTTGCATG) and oligonucleotide D (CGTCGCAGTAACTGTTGCTTGCA
GTACACAC). PCR was performed in 10 mM Tris z HCl (pH 9.0)–2 mM
MgCl2–50 mM KCl–0.01% gelatin–0.1% Triton X-100–0.5 U of Thermus ther-
mophilus (Tth) DNA polymerase (Sphaero Q, Leiden, The Netherlands). Nu-
cleotide triphosphates were present at 0.2 mM each. The amplification program
consisted of 35 cycles of 1 min at 948C, 1 min at 608C, and 2 min at 748C, followed
by a final extension step of 10 min at 748C. Reaction products were analyzed on
1.5% agarose gels, run in 40 mM sodium acetate (pH 6.0)–1 mM EDTA (500
V z h). Gels were stained with ethidium bromide and photographed (Polaroid
Polapan-60 films; Kodak, Amsterdam, The Netherlands). If reamplification was
required, samples were run on low-melting-point agarose (FMC). Bands were
cut out of these gels and redissolved in 0.5 ml of 10 mM Tris z HCl (pH 8.0)–1
mM EDTA, which served as a stock solution for subsequent reamplifications.
SSCP analyses. By using the purified DNA fragments (see above) as tem-
plates, increasing both the Tth polymerase concentration and the amount of
primers by a factor of 3, and adding 0.75 ml of [a-32P]dATP (3,000 Ci/mmol;
Amersham plc), the AB fragment (the fragment amplified with primers A and B)
could be homogeneously labeled during the PCR. After digestion with the
restriction enzyme HhaI (27), the sample was diluted 10-fold by the addition of
96% formamide containing bromophenol blue and xylene cyanol. Samples were
heated at 1008C for 10 to 15 min and immediately cooled on ice. Electrophoresis
was performed on 10% polyacrylamide gels (acrylamide/bisacrylamide ratio,
15:1) containing 0.089 M Tris z borate (pH 8.0), 0.089 M boric acid, and 8 mM
EDTA. The temperature was set at 48C, the voltage was fixed to a value of 500
V, and electrophoresis was continued for 16 h. The gels were subsequently dried,
and autoradiography was performed overnight at 2708C (X-Omat AR films;
Kodak).
Direct sequence analysis. Sequence data were obtained for the AB fragments
from clinical specimens of all patients. From a subset of clinical samples, a small
region from within the CD fragment also was sequenced. DNA fragments suited
for sequencing studies were generated by a nonradioactive PCR as described
above. The only difference was that either primer A or primer C was derivatized
with a 59 biotin group. After PCR, the DNA fragments were bound to strepta-
vidin-coated magnetic beads (Dynabeads M280; Dynal, Oslo, Norway) and
washed twice with a buffer containing 50 mM Tris z HCl (pH 8.0), 100 mM NaCl,
and 1 mM EDTA. The nonbiotinylated strand was eluted by treatment with 0.1
M NaOH. DNA was sequenced by standard dideoxy chain termination methods
with the T7 DNA sequencing kit (Pharmacia, Uppsala, Sweden) by using a-35S-
dATP (3,000 Ci/mmol; Amersham plc) as the radioactive tracer. Sequencing
products were separated on 5 or 8% polyacrylamide gels. DNA sequences were
read manually from the autoradiographs, and sequence manipulations and com-
parisons were performed with the PC/gene computer program (Intelligenetics
Inc., Mountain View, Calif.).P
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RESULTS
Comparison of patient groups. All groups of patients were
comparable with respect to median age, smoking habits, age at
date of first intercourse, and use of oral contraceptives (Table
2 and reference 20 give more-detailed descriptions). Among
the people with multiple heterosexual partners, selected in
Amsterdam, an increased frequency of infections caused by
sexually transmittable pathogens is apparent. All of these in-
dividuals had a history of STD. Among the monogamous fe-
males from Delft and the gynecological patients from Gronin-
gen, only a limited number of past STD infections were
documented (33 and 14% of the women, respectively). An-
other major difference among groups was the number of recent
sexual partners, which averaged 78 in the past 4 months for the
Amsterdam individuals. In the Delft and Groningen groups,
the average lifetime numbers of sexual partners were 4 and 5,
respectively, and all of these women had had a single partner
for the previous 5 years. The females from Groningen had
been diagnosed with cervical neoplasia. They were chosen at
random from a larger group of cervical neoplasia patients.
Upon cytological screening for cervical carcinoma, their cervi-
cal intraepithelial neoplasia classes were found to be II or
higher, and patients 28, 31, and 32 underwent surgery for
cervical carcinoma. This constitutes a major difference from
the other groups, in which an incidental cervical intraepithelial
neoplasia class I lesion provided the highest grade of cervical
neoplasia (results not shown).
Amplification of HPV16 DNA from clinical samples. With
the AB and CD primer combinations, DNA fragments of the
correct length were synthesized when CasKi DNA was used as
a template during PCR. No cross-reactivity of the primers with
HPV6/11, HPV18, HPV31, and HPV33 DNA was observed,
and human DNA was also not amplified (results not shown).
Of the initial set of clinical materials (n 5 97), which were all
proven HPV16 DNA positive by amplification of a region
within the E6 gene (24), only 69% (n 5 67) gave a positive
result when primers A and B or C and D were applied. Addi-
tion of more DNA or elevation of the primer or Taq poly-
merase concentration did not have a positive effect (results not
shown). This indicates that the AB and CD PCR assays are not
as sensitive as the one used for HPV16 diagnosis (17). No
differences in the percentages of negative samples among the
geographically diverse groups were observed. Nonamplifiable
samples were excluded from the study.
Technical aspects of SSCP. For optimization of SSCP, the
denaturation step had to be prolonged and performed at an
elevated temperature in comparison with previously published
protocols (27). An acrylamide/bisacrylamide ratio of 15:1 in
the polyacrylamide gels rendered the most suitable matrix for
electrophoretic strand separation (Fig. 1). The results are sur-
veyed in Table 1. No SSCP data were generated for the HPV16
isolates from Groningen and Nijmegen since the resolution of
SSCP appeared to be far less than that of DNA sequencing
(see below).
Technical aspects of genomic sequencing of HPV16 ampli-
cons. A small pilot study revealed that more sequence variabil-
ity was observed among the AB fragments than among the CD
amplimers. For this reason, nucleotide sequences of the AB
fragments were determined for all HPV16 isolates. A fragment
of about 290 bp from the region bordered by nucleotides 7177
and 7463 (10, 22) was fully characterized. No molecular clon-
ing of the PCR fragments was performed, which may be a
reason why mixed infections were missed. The direct-sequenc-
ing approach highlights only the most prevalent HPV16 variant
in a mixture of viruses. Mutations are displayed in Table 2,
where a sequence comparison of all HPV16 types is given.
These sequencing results were not compromised by sequencing
part of the CD fragment. Those data appeared, however, to be
less discriminatory (results not shown). From Table 1, it can be
concluded that the resolution of DNA sequencing exceeds that
of SSCP. For instance, SSCP cannot discriminate among se-
quence types I, III, IV, VI, VII, and VIII, which leads to an
underestimation of the actual number of sequence variants.
Viral epidemiology and persistence. The HPV16 strains
from the promiscuous people (Amsterdam) were of four dif-
ferent HPV types, as identified by SSCP. Among the HPV16
isolates from the monogamous females from Delft, only a
single SSCP pattern (based on the analysis of the AB frag-
ment) was observed. This indicates the presence of a geneti-
cally more homogeneous group of HPV16 strains in the Delft
population. By genomic sequencing, it was determined that the
Amsterdam population harbored nine genetically distinct vari-
ants of HPV16. Only two sequence variants were detected
among the 14 females from Delft. One of these DNA se-
quences was identical to that of the strain from Nijmegen.
Among the patients from Groningen, four variants were de-
tected. Results obtained by SSCP and sequencing of amplified
HPV16 DNA from women sampled longitudinally do not vary;
moreover, the two methods do not seem to detect differences
among partial HPV16 sequences of isolates from various an-
atomical locations in individual patients (Table 1).
DISCUSSION
A large percentage of humans are infected by one of the
many known HPVs. It has even been documented that a single
individual can harbor multiple strains of a single viral type (11).
This was not confirmed in the present study, perhaps because
of the omission of a molecular cloning step. It has also been
suggested that the presence of multiple HPV types in a single
lesion may be dependent on the immune status of the patient
involved (3). The identity of the longitudinal isolates was in-
dependent of sexual promiscuity. Whether promiscuous indi-
TABLE 2. Survey of demographic and patient-related dataa
Patient class Geographicorigin Age
%
Smokers
Age at first
intercourse (yr)
No. of sex
partnersb
STD partner
(%)c
STD history
(%)d
% Using oral
contraceptives
Promiscuous Amsterdam 34 82 17 78 100 100 43
Monogamous Delft 39 66 16 1 (4) 33 33 67
Neoplasia Groningen 40 71 18 1 (5) NKe 14 57
a Data are given as averages. STDs monitored for were herpes simplex virus types 1 and 2, syphilis, gonorrheae, chlamydia, and trichomoniasis.
b Average per month calculated over the 4 months prior to interview and sampling. For monogamous females from Delft and Groningen, the average lifetime number
of partners is given in parentheses.
c Percentage of HPV16-positive patients who had sex with a partner suffering from an STD.
d Percentage of HPV16-positive patients who had suffered once or more from an STD.
e NK, not known.
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viduals, who remained at high risk for acquiring an HPV16
reinfection, or monogamous females are considered, HPV16
variants seem to be very persistent. Interestingly, all individuals
from Amsterdam and two of three females from Delft, who
were persistently HPV16 positive, were infected by a single
HPV16 genotype. Whether this is a variant which specifically
causes persistent infection or whether this is just the most
prevalent Dutch genotype is the subject of current investiga-
tions. Since it has recently been demonstrated that high-risk
HPV types can be transmitted quite easily by sexual inter-
course (15), the fact that infection by HPV16 seems to pre-
clude reinfection by another variant may have important im-
plications for future vaccination strategies using attenuated
HPV16 vaccine strains.
It is interesting that the group of HPVs collected from the
monogamous females seems to be less heterogeneous than the
one from the Amsterdam heterosexuals with multiple partners
originating from different countries (2 types among 14 individ-
uals versus 9 types among 20 individuals; Fisher’s exact test,
P 5 0.07). This is concordant with earlier observations of
geographic clustering of HPV16 variants on the basis of se-
quence divergence in the E7 gene (2). Moreover, it seems
logical to assume that among sexually promiscuous individuals,
the number of HPV16 variants encountered will be larger than
that for the more monogamous population in Delft. An ab-
sence of differences in serological response between persis-
tently and incidentally infected persons has been documented
previously (25).
The mutations at positions 7191, 7192, and 7193 are bor-
dered by a directly repeated motif (59-TGTTTGT-39). In the
region around mutation positions 7429 to 7447, another, even
larger direct repeat (59-ATTTTGTAGC-39) can be identified.
The role of these repeats in mutagenesis is not immediately
clear, but it could be that during replication, distinct repeats
could form heteroduplexes with their neighboring counter-
parts, thereby rendering the intermittent region single stranded
and vulnerable to mutagenic effects. No conclusions concerning
the positions of base changes and the possible effects on promot-
ers, enhancers, and protein binding sites in the HPV16 noncoding
region in relation to biological effects (persistence, virulence, on-
cogenic potential, etc.) can be made as yet.
Among the promiscuous individuals from Amsterdam, SSCP
revealed four genotypes of HPV16 in 20 individuals. This cor-
relates well with previous data (27) documenting the occur-
rence of 12 variants in 48 patients. It was claimed that SSCP is
as sensitive as direct sequencing, but in our present study we
noticed that several sequence variants remain undetected by
SSCP. Among the same 20 strains of HPV16, nine sequence
types were found. All different SSCP types represent sequence
variants, but not all variant sequences give rise to SSCP alter-
ations. This implies that for epidemiological studies, direct
sequencing of PCR products should be preferred over SSCP
analysis of the same fragments.
It appears that a single genotype of HPV16 can persist over
many years in a single individual. In the present study, the
maximum length of follow-up was 3 years. This persistency may
be an important step, ultimately leading to oncogenic trans-
formation, and the possibility that acquisition of a strain which
gives rise to persistent infection may predispose an individual
to development of cytological abnormalities cannot be ex-
cluded. In order to draw definite conclusions, additional stud-
ies of HPV16 spreading and epidemiology must be performed
on a larger scale.
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FIG. 1. Example of SSCP analysis of internally 32P-labeled PCR-amplified HPV16 DNA (AB fragment) deriving from people with multiple sex partners in
Amsterdam. Numbering of the lanes corresponds to numbering of patients as given in Table 1.
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